GSM Therapies Compared: Local Estrogen Remains Benchmark

Genitourinary syndrome of menopause significantly impairs vulvovaginal health and overall quality of life. Consequently, clinicians often face diverse therapeutic choices for symptomatic postmenopausal patients. These choices include hormonal suppositories, oral agents, lubricants, and novel energy-based devices. However, comparative evidence across these options has historically remained scattered and inconsistent.

A landmark systematic review and network meta-analysis synthesised evidence from twenty-four unique clinical trial families. Specifically, the researchers evaluated forty-nine hundred fifty-eight randomized participants. Furthermore, their rigorous analysis clarifies which interventions deliver reproducible symptom relief.

Network Meta-Analysis on Genitourinary Syndrome of Menopause

The comprehensive network meta-analysis evaluated patient-reported symptom burden across seven distinct therapeutic classes. Notably, local vaginal oestrogen emerged as the only intervention with a confidence interval excluding the null. Therefore, local oestrogen demonstrated statistically significant symptom improvement compared to placebo or sham therapies. In contrast, researchers observed imprecise estimates for several non-hormonal and hormonal alternatives. These alternatives included intravaginal prasterone, oral ospemifene, hyaluronic acid preparations, and personal moisturizers.

Moreover, procedural modalities showed disappointing results in the primary network synthesis. Specifically, carbon dioxide laser therapy yielded negligible improvement over sham interventions. Furthermore, investigators could not incorporate radiofrequency therapy into the primary analysis due to missing continuous dispersion data. Consequently, current evidence fails to position energy-based devices as superior or equivalent first-line options.

Clinical Implications for Practice

Consequently, clinicians should continue to position low-dose vaginal oestrogen as the primary benchmark therapy. However, physicians must tailor care when patients present with specific contraindications. For instance, breast cancer survivors frequently require non-hormonal strategies initially. Therefore, hyaluronic acid and prescription lubricants serve as practical starting steps. In addition, prasterone offers a viable hormonal alternative where appropriate. Ultimately, clinical guidelines advocate for an individualized stepped-care strategy rather than an inflexible treatment hierarchy supported by advanced training through an advanced clinical practice program in urogynaecology.

Frequently Asked Questions

Q1: Why does local vaginal estrogen remain the benchmark therapy?

Local vaginal estrogen consistently demonstrates statistically significant improvement in patient-reported symptoms. Furthermore, it was the only therapy in the meta-analysis with confidence intervals that excluded the null.

Q2: Are energy-based treatments like vaginal lasers recommended as first-line options?

Current clinical evidence does not support vaginal lasers or radiofrequency as first-line therapies. In addition, carbon dioxide laser therapy showed negligible superiority over sham treatments in randomized trials.

Q3: How should clinicians approach patients who cannot use estrogen?

Clinicians should implement a stepped-care model using non-hormonal moisturizers or hyaluronic acid. Moreover, intravaginal prasterone represents an alternative prescription option depending on the patient's specific oncologic profile.

References

1. Randombage PJS et al. Comparative Efficacy and Safety of Modern Treatment Modalities for Genitourinary Syndrome of Menopause: A Systematic Review and Network Meta-Analysis. BJOG. 2026 Nov 08. doi: 10.1111/1471-0528.70370. PMID: 43000041.
2. Meeta M, Anuradha M, Ashraf AB, Aggarwal K, Digumarti L, Singh T. Clinical Practice Guidelines for Menopause: An Executive Summary and Recommendations: Indian Menopause Society 2026. J Midlife Health. 2026;17(Suppl 1):S12-S116.
3. The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society. Menopause. 2020;27(9):976-992.